Biomarker heterogeneity and efficacy of durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib in patients with mismatch repair proficient endometrial cancer: exploratory analyses of the DUO-E/GOG-3041/ENGOT-EN10 trial.

Westin SN, Moore K, Chon HS, Pepin JT, Salinas EA, Starks D, Disilvestro PA, Slomovitz B, Vettus E, Gálvez-Montosa F, Agyemang-Prempeh K, Zagouri F, Kim JW, Gao Q, Mejia FC, De Melo AC, Nishikawa T, Kowgier M, Iyer S, Wang Y, Van Nieuwenhuysen E

Open source

DOI: 10.1016/j.ygyno.2026.01.777
Published: 2026 Mar
Container: Gynecologic oncology
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.ygyno.2026.01.777,
  title = {Biomarker heterogeneity and efficacy of durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib in patients with mismatch repair proficient endometrial cancer: exploratory analyses of the DUO-E/GOG-3041/ENGOT-EN10 trial.},
  author = {Westin SN and Moore K and Chon HS and Pepin JT and Salinas EA and Starks D and Disilvestro PA and Slomovitz B and Vettus E and Gálvez-Montosa F and Agyemang-Prempeh K and Zagouri F and Kim JW and Gao Q and Mejia FC and De Melo AC and Nishikawa T and Kowgier M and Iyer S and Wang Y and Van Nieuwenhuysen E},
  year = {2026},
  journal = {Gynecologic oncology},
  doi = {10.1016/j.ygyno.2026.01.777},
  url = {https://doi.org/10.1016/j.ygyno.2026.01.777}
}

RIS

TY  - JOUR
TI  - Biomarker heterogeneity and efficacy of durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib in patients with mismatch repair proficient endometrial cancer: exploratory analyses of the DUO-E/GOG-3041/ENGOT-EN10 trial.
AU  - Westin SN
AU  - Moore K
AU  - Chon HS
AU  - Pepin JT
AU  - Salinas EA
AU  - Starks D
AU  - Disilvestro PA
AU  - Slomovitz B
AU  - Vettus E
AU  - Gálvez-Montosa F
AU  - Agyemang-Prempeh K
AU  - Zagouri F
AU  - Kim JW
AU  - Gao Q
AU  - Mejia FC
AU  - De Melo AC
AU  - Nishikawa T
AU  - Kowgier M
AU  - Iyer S
AU  - Wang Y
AU  - Van Nieuwenhuysen E
PY  - 2026
JO  - Gynecologic oncology
DO  - 10.1016/j.ygyno.2026.01.777
UR  - https://doi.org/10.1016/j.ygyno.2026.01.777
ER  -

APA

SN, W., K, M., HS, C., JT, P., EA, S., D, S., PA, D., B, S., E, V., F, G., K, A., F, Z., JW, K., Q, G., FC, M., AC, D. M., T, N., M, K., S, I., Y, W., & E, V. N. (2026). Biomarker heterogeneity and efficacy of durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib in patients with mismatch repair proficient endometrial cancer: exploratory analyses of the DUO-E/GOG-3041/ENGOT-EN10 trial.. Gynecologic oncology. https://doi.org/10.1016/j.ygyno.2026.01.777

Source records

pubmed · retrieved 2026-09-26T17:16:21.639Z